Clinical Trial Detail

NCT ID NCT02987166
Title HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors James Larner, MD
Indications

Advanced Solid Tumor

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.